Publications by authors named "Erin Quirk"

Claim this Profile
T
TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trial.
Mazen Noureddin, Naim Alkhouri, Eric J Lawitz, Kris V Kowdley, Rohit Loomba, Erin Quirk

Nat Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A corpus-assisted discourse study of parental concerns regarding multilingual child-rearing.
Erin Quirk, Melanie Brouillard, Alexa Ahooja, Susan Ballinger, Linda Polka

J Multiling Multicult Dev· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reading in two languages: Parents' strategy and language use across book formats during bilingual shared reading.
Erin Quirk, Melanie Brouillard, Krista Byers-Heinlein

Biling Res J· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trilingual families' language strategies: potential predictors and effect on trilingual exposure.
Erin Quirk, Natasha Hadeed, Krista Byers-Heinlein

Int J Multiling· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quebec-based parents' concerns regarding their children's multilingual development.
Erin Quirk, Melanie Brouillard, Alexa Ahooja, Susan Ballinger, Linda Polka

Int J Multiling· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quebec-based Parents' Attitudes Towards Childhood Multilingualism: Evaluative Dimensions and Potential Predictors.
Ruth Kircher, Erin Quirk, Melanie Brouillard, Alexa Ahooja, Susan Ballinger

J Lang Soc Psychol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Family language policy among Québec-based parents raising multilingual infants and toddlers: A study of resources as a form of language management.
Alexa Ahooja, Melanie Brouillard, Erin Quirk, Susan Ballinger, Linda Polka

J Multiling Multicult Dev· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Pharmacokinetics, Pharmacodynamics, and Formulation of Liver-Distributed Farnesoid X-Receptor Agonist TERN-101 in Healthy Volunteers.
Yujin Wang, Daria B Crittenden, Clarence Eng, Qiong Zhang, Pengfei Guo, Erin Quirk

Clin Pharmacol Drug Dev· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
Kristen Andreatta, Madeleine Willkom, Ross Martin, Silvia Chang, Lilian Wei, Erin Quirk

J Antimicrob Chemother· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to: Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
Kristen Andreatta, Madeleine Willkom, Ross Martin, Silvia Chang, Lilian Wei, Erin Quirk

J Antimicrob Chemother· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial.
Cissy Kityo, Debbie Hagins, Ellen Koenig, Anchalee Avihingsanon, Ploenchan Chetchotisakd, Erin Quirk

J Acquir Immune Defic Syndr· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virological outcomes of EVG/COBI/FTC/TDF and EVG/COBI/FTC/TAF in antiretroviral-naive HIV-1-infected participants with baseline HIV-1 RNA ≥1,000,000 copies/ml: a post hoc analysis of Phase III clinical trials.
Paul Sax, Edwin DeJesus, David Wohl, Jennifer DeMorin, Damian McColl, Erin Quirk

Antivir Ther· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks.
Rima K Acosta, Madeleine Willkom, Ross Martin, Silvia Chang, Xuelian Wei, Erin Quirk

Antimicrob Agents Chemother· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine.
David Wohl, Amanda Clarke, Franco Maggiolo, Will Garner, Marianne Laouri, Erin Quirk

Patient· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Jean-Michel Molina, Douglas Ward, Indira Brar, Anthony Mills, Hans-Jürgen Stellbrink, Erin Quirk

Lancet HIV· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.
Eric S Daar, Edwin DeJesus, Peter Ruane, Gordon Crofoot, Godson Oguchi, Erin Quirk

Lancet HIV· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repeat testing of low-level HIV-1 RNA: assay performance and implementation in clinical trials.
Kirsten White, Will Garner, Lilian Wei, Joseph J Eron, Lijie Zhong, Erin Quirk

AIDS· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Joel Gallant, Adriano Lazzarin, Anthony Mills, Chloe Orkin, Daniel Podzamczer, Erin Quirk

Lancet· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Paul E Sax, Anton Pozniak, M Luisa Montes, Ellen Koenig, Edwin DeJesus, Erin Quirk

Lancet· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1-Infected Adults.
Joel E Gallant, Melanie Thompson, Edwin DeJesus, Gene W Voskuhl, Xuelian Wei, Erin Quirk

J Acquir Immune Defic Syndr· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
Edwin DeJesus, Moti Ramgopal, Gordon Crofoot, Peter Ruane, Anthony LaMarca, Erin Quirk

Lancet HIV· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
Chloe Orkin, Edwin DeJesus, Moti Ramgopal, Gordon Crofoot, Peter Ruane, Erin Quirk

Lancet HIV· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
Paul E Sax, Edwin DeJesus, Gordon Crofoot, Douglas Ward, Paul Benson, Erin Quirk

Lancet HIV· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.
Aditya H Gaur, Hilda Kizito, Wasana Prasitsueubsai, Natella Rakhmanina, Mohammed Rassool, Erin Quirk

Lancet HIV· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety Profile of the Merck Human Immunodeficiency Virus-1 Clade B gag DNA Plasmid Vaccine With and Without Adjuvants.
Erin K Quirk, Elizabeth L Brown, Randi Y Leavitt, Robin Mogg, Devan V Mehrotra

Open Forum Infect Dis· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis